Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Indias Gamechanger: #DigitalRupee
- FASTag rule change: Blacklisted accounts will have window of 60 minutes before and 10 minutes after crossing toll plaza for having smooth journey ahead
- RBI MPC 2025 Highlights: Endeavour of RBI to provide as much as liquidity as required, says RBI Guv
- Frontier Markets’ Largest Women Empowerment Programme ‘She-Leads Bharat’ to Invest in 1MN Rural Women and 100MN Households of India
